Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CA5-C82E9 | Cynomolgus | Biotinylated Cynomolgus CA125 / MUC16 Protein, His,Avitag™ (MALS verified) |  |
|
|
| CA5-M52H6 | Mouse | Mouse CA125 / MUC16 Protein, His Tag (MALS verified) |  |
|
|
| CA5-C52H8 | Cynomolgus | Cynomolgus CA125 / MUC16 Protein, His Tag (MALS verified) |  |
|
|
| CA5-R52H3 | Rhesus macaque | Rhesus macaque CA125 / MUC16 (12664-12920) Protein, His Tag (MALS verified) |  |
|
|
| CA5-R52H6 | Rhesus macaque | Rhesus macaque CA125 / MUC16 (13647-14291) Protein, His Tag (MALS verified) |  |
|
|
| CA5-H52H6 | Human | Human CA125 / MUC16 (13810-14451) Protein, His Tag (MALS verified) |  |
|
|
| CA5-H82F8 | Human | Biotinylated Human CA125 / MUC16 (13810-14451) Protein, Fc,Avitag™ |  |
|
|
| CA5-H82F4 | Human | Biotinylated Human CA125 / MUC16 Protein, Fc,Avitag™ |  |
|
|
Biotinylated Mouse Mesothelin, His,Avitag (Cat. No. MSN-M82E7) immobilized on CM5 Chip can bind Mouse CA125 Protein, His Tag (Cat. No. CA5-M52H6) with an affinity constant of 16.4 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Oregovomab | B43.13 | Phase 3 Clinical | Paladin Pharma | Ovarian Neoplasms; Abdominal Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| LBL-033 | LBL-033 | Phase 2 Clinical | Nanjing WeiLibo biological Technology Co Ltd | Neoplasms | Details |
| REGN-5668 | REGN-5668 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms | Details |
| Ubamatamab | REGN-4018 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Ovarian Neoplasms; Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms | Details |
| PRGN-3005 | PRGN-3005 | Phase 1 Clinical | Precigen Inc | Ovarian Neoplasms; Esophageal Neoplasms; Sarcoma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Uterine Cervical Neoplasms | Details |
| JCAR-020 | JCAR-020 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc | Solid tumours | Details |
| Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy(Regeneron Pharmaceutical) | 27T-51; 27T51 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
